TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
TransMedics Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$71.60+0.82 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- 18.6
- Dividend yield
- 0.00%
Share price
−$46.03 (−39.13%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TransMedics Group, Inc. grew revenue 25.8% to $668.47M over the twelve months to Jun 30, 2026. Operating income rose 6.6% to $81.61M, moving the operating margin from 14.4% to 12.2%. Free cash flow was $79.04M, up 355.5% from a year earlier.
Revenue
$668.47M
+25.8% vs. a year earlier
Operating income
$81.61M
+6.6% vs. a year earlier
Free cash flow
$79.04M
+355.5% vs. a year earlier
EPS, diluted
$3.85
+99.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.91B
- P/E ratio
- 18.6
- Price to sales
- 4.36
- Price to book
- 5.63
- Dividend yield
- 0.00%
- Free cash flow yield
- 2.71%
Fundamentals
- Revenue
- $668.47M
- Net income
- $151.70M
- EPS, diluted
- $3.85
- Free cash flow
- $79.04M
- Book value per share
- $12.73
- Diluted shares
- 41M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$668.47M+25.8% YoY
Gross profit
$392.35M+23.5% YoY
Operating income
$81.61M+6.6% YoY
Net income
$151.70M+111.7% YoY
EPS, diluted
$3.85+99.5% YoY
Free cash flow
$79.04M+355.5% YoY
Reported periodTrailing twelve months